Antibodies Monoclonal Therapeutic Use
Mostrando 1-12 de 39 artigos, teses e dissertações.
-
1. The relevance of a bank with genotyped platelets donors
ABSTRACT Objective: Describe the clinical and laboratory characteristics and the transfusion strategy of patients at Hospital Israelita Albert Einstein with platelet refractoriness and identify their etiological characteristics. Standardize the platelet immunofluorescence technique by flow cytometry as a test for platelet compatibility in immune platelet re
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
2. Advances and challenges in therapeutic monoclonal antibodies drug development
The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since th
Braz. J. Pharm. Sci.. Publicado em: 08/11/2018
-
3. Aptamers as a promising approach for the control of parasitic diseases
ABSTRACT Aptamers are short single-stranded RNA or DNA oligonucleotides that are capable of binding various biological targets with high affinity and specificity. Their identification initially relies on a molecular process named SELEX (Systematic Evolution of Ligands by EXponential enrichment) that has been later modified in order to improve aptamer sensiti
Braz J Infect Dis. Publicado em: 2016-12
-
4. Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
Two classes of epidermal growth factor receptor (EGFR) inhibitors are currently available for clinical use: tyrosine-kinase inhibitors (TKIs) and monoclonal antibodies. The introduction of pharmacological agents that are able to inhibit EGFR represents an important step in the management of patients with advanced non-small cell lung cancer (NSCLC), the leadi
Revista da Associação Médica Brasileira. Publicado em: 2012-04
-
5. Dendritic cells (DC) generation from peripheral blood mononuclear cells obtained from jaundiced patients with pancreatic adenocarcinoma. / Análise de células mononucleares mantidas em cultura em meio propício para geração de células dendríticas obtidas de pacientes com câncer de pâncreas.
Pancreatic adenocarcinoma (PAdc) is an aggressive malignancy with poor prognosis, urging for improved or new therapeutic strategies. DC-based vaccination is one of such promising approaches. DC are the most potent antigen-presenting cells and central to the induction and maintenance of an immune response. However, in cancer patients DC generation and functio
Publicado em: 2008
-
6. Resultado do tratamento da doença de Crohn com anti-fator de necrose tumoral alfa / Outcomes in the treatment of Crohn´s disease with anti tumor necrososis factor-alpha
A doença de Crohn é uma inflamação crônica do trato gastrointestinal. O tratamento convencional é muitas vezes desapontador. Apesar da variedade de drogas disponíveis para o tratamento da doença inflamatória intestinal, tais como: salicilatos e seus derivados, corticosteróides, antibióticos e imunossupressores, nenhuma destas mostrou ser totalment
Publicado em: 2008
-
7. Mecanismos moleculares da neutralização da atividade letal das toxinas escorpiônicas por anticorpos monoclonais e policlonais
The major goal of this thesis is the immunochemical study of the scorpion toxins. Four manuscripts were presented concerning this subject. In the first report, a detoxified immunogen was prepared by conjugation of a toxic fraction (TstFG50), of the T. serrulatus venom, with bovine serum alburnin (BSA). The immunogen was inject in mice for inducing antibodies
Publicado em: 2007
-
8. Humanized antibodies for antiviral therapy.
Antibody therapy holds great promise for the treatment of cancer, autoimmune disorders, and viral infections. Murine monoclonal antibodies are relatively easy to produce but are severely restricted for therapeutic use by their immunogenicity in humans. Production of human monoclonal antibodies has been problematic. Humanized antibodies can be generated by in
-
9. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?
While monoclonal antibodies show promise for use in the treatment of a variety of disease states, including cancer, autoimmune disease, and allograft rejection, generation of anti-antibody responses still remains a problem. For example, 50% of the patients who receive OKT3 produce blocking antibodies that interfere with its binding to T cells, thus decreasin
-
10. Understanding and circumventing resistance to anticancer monoclonal antibodies
With the widespread use of therapeutic monoclonal antibodies in the treatment of patients with cancer, resistance to these agents has become a major issue. Preclinical models of drug action or resistance have contributed to unravel the main mechanisms of resistance, involving both tumor-associated and host related factors. However our understanding of how a
Landes Bioscience.
-
11. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment.
We have prepared bispecific, cross-linked monoclonal antibodies (heteropolymers) with specificity for both targeted antigens and the human erythrocyte (RBC) complement receptor. These heteropolymers facilitate binding of target antigens (human IgG and dinitrophenylated bovine gamma globulin) to human RBCs under conditions that either allow or preclude comple
-
12. Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.
Monoclonal antibodies specific for the five major glycoproteins of herpes simplex virus type 1 (HSV-1) were tested for their capacity to mediate immunity to ocular HSV-1 infection. The specificity of the immunoglobulin made by each monoclone was determined by immunoprecipitation of [14C]glucosamine-labeled polypeptides from detergent-solubilized HSV-1-infect